{"generic":"Carvedilol","drugs":["Carvedilol","Coreg"],"mono":{"0":{"id":"jt69s0","title":"Generic Names","mono":"Carvedilol"},"1":{"id":"jt69s1","title":"Dosing and Indications","sub":[{"id":"jt69s1b4","title":"Adult Dosing","mono":"<ul><li><b>Acute ST segment elevation myocardial infarction:<\/b> initial, 6.25 mg ORALLY twice daily; initiate within 24 hours of ST-segment elevation myocardial infarction; titrate as tolerated to target dose of 25 mg twice daily<\/li><li><b>Angina pectoris, chronic:<\/b> 25 to 50 mg ORALLY twice daily<\/li><li><b>Heart failure:<\/b> initial, 3.125 mg ORALLY twice daily for 2 weeks; dose may be doubled every 2 weeks to highest dose tolerated; MAX dose, patients weighing less than 85 kg, 25 mg ORALLY twice daily; MAX dose, patients weighing more than 85 kg, 50 mg ORALLY twice daily<\/li><li><b>Hypertension:<\/b> initial, 6.25 mg ORALLY twice daily; dose may be doubled every 1 to 2 weeks; maximum dose, 25 mg ORALLY twice daily<\/li><li><b>Impaired left ventricular function - Myocardial infarction:<\/b> initial, 6.25 mg ORALLY twice daily; dose may be increased after 3 to 10 days as tolerated to 12.5 mg twice daily, then again to target\/MAX dose of 25 mg twice daily<\/li><\/ul>"},{"id":"jt69s1b5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established in pediatric patients "},{"id":"jt69s1b6","title":"Dose Adjustments","mono":"<ul><li><b>hemodialysis:<\/b> dosing adjustments are not required<\/li><li><b>liver disease:<\/b> initial, 20% of the normal dose recommended in one study; contraindicated in severe liver impairment<\/li><\/ul>"},{"id":"jt69s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Heart failure<\/li><li>Hypertension<\/li><li>Impaired left ventricular function - Myocardial infarction<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Acute ST segment elevation myocardial infarction<\/li><li>Angina pectoris, chronic<\/li><li>Atrial arrhythmia<\/li><li>Cardiac dysrhythmia<\/li><li>Congestive cardiomyopathy<\/li><li>Congestive heart failure, Nitrate tolerance<\/li><li>Disease of liver<\/li><li>Doxorubicin adverse reaction - Left ventricular cardiac dysfunction; Prophylaxis<\/li><li>Gastroesophageal varices; Prophylaxis<\/li><li>Surgical procedure<\/li><\/ul>"}]},"3":{"id":"jt69s3","title":"Contraindications\/Warnings","sub":[{"id":"jt69s3b9","title":"Contraindications","mono":"<ul><li>bronchial asthma or related bronchospastic condition; status asthmaticus resulting in death has been reported<\/li><li>cardiogenic shock<\/li><li>decompensated heart failure requiring IV inotropic therapy<\/li><li>hypersensitivity, including Stevens-Johnson syndrome, anaphylactic reaction, and angioedema, to carvedilol or any component of the product<\/li><li>second or third degree atrioventricular block<\/li><li>severe bradycardia, if no pacemaker is present<\/li><li>severe hepatic impairment<\/li><li>sick sinus syndrome<\/li><\/ul>"},{"id":"jt69s3b10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- use caution in patients with ischemic heart disease, diffuse vascular disease, or hypotension (systolic blood pressure less than 100 mmHg) since renal function deterioration has been reported; reduce dosage or discontinue if worsening renal function occurs<\/li><li>-- heart failure may worsen during dose increases; temporary discontinuation or dose reduction may be necessary<\/li><li>-- may provoke chest pain in patients with Prinzmetal's variant angina<\/li><li>-- patients with peripheral vascular disease may experience precipitation or worsening of arterial insufficiency<\/li><li>-- bradycardia, with pulse rate below 55 beats\/minute, may occur; dose reduction may be necessary<\/li><li>-- syncope or postural hypotension have occurred, especially during initiation of therapy<\/li><li>-- avoid abrupt withdrawal, especially in patients with coronary artery disease, as myocardial infarction, ventricular arrhythmia, and exacerbation of angina have been reported<\/li><li>Endocrine and Metabolic:<\/li><li>-- pheochromocytoma<\/li><li>-- use caution in patients with thyrotoxicosis as clinical signs of hyperthyroidism, such as tachycardia, may be masked; abrupt withdrawal may exacerbate symptoms or precipitate thyroid storm<\/li><li>-- in patients with diabetes mellitus, may mask symptoms of hypoglycemia, such as tachycardia; may worsen hyperglycemia in congestive heart failure patients<\/li><li>Immunologic:<\/li><li>-- history of anaphylactic reaction to varied allergens may increase reactivity and decrease response to epinephrine<\/li><li>Ophthalmic:<\/li><li>-- use caution during cataract surgery due to risk of intraoperative floppy iris syndrome; may require modification of surgical technique<\/li><li>Renal:<\/li><li>-- use caution in patients with renal insufficiency since renal function deterioration has been reported; reduce dosage or discontinue if worsening renal function occurs<\/li><li>Respiratory:<\/li><li>-- not recommended in patients with bronchospastic disease, including chronic bronchitis and emphysema; if use is warranted, use the smallest effective dose<\/li><li>Other:<\/li><li>-- may impair ability of heart to respond to reflex adrenergic stimuli during major surgery and anesthesia<\/li><\/ul>"},{"id":"jt69s3b11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"jt69s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jt69s4","title":"Drug Interactions","sub":[{"id":"jt69s4b13","title":"Contraindicated","mono":"<ul>Colchicine (theoretical)<\/ul>"},{"id":"jt69s4b14","title":"Major","mono":"<ul><li>Afatinib (theoretical)<\/li><li>Albuterol (theoretical)<\/li><li>Amiodarone (established)<\/li><li>Apixaban (theoretical)<\/li><li>Arformoterol (theoretical)<\/li><li>Bambuterol (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Bupropion (theoretical)<\/li><li>Clenbuterol (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Colterol (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Diltiazem (probable)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Dronedarone (probable)<\/li><li>Epinephrine (probable)<\/li><li>Everolimus (theoretical)<\/li><li>Fenoldopam (theoretical)<\/li><li>Fenoterol (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Hexoprenaline (theoretical)<\/li><li>Indacaterol (theoretical)<\/li><li>Iobenguane I 123 (theoretical)<\/li><li>Isoetharine (theoretical)<\/li><li>Lacosamide (theoretical)<\/li><li>Levalbuterol (theoretical)<\/li><li>Metaproterenol (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Olodaterol (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Paroxetine (theoretical)<\/li><li>Pirbuterol (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Procaterol (theoretical)<\/li><li>Reproterol (theoretical)<\/li><li>Ritodrine (theoretical)<\/li><li>Rivastigmine (theoretical)<\/li><li>Romidepsin (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Terbutaline (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Tretoquinol (theoretical)<\/li><li>Tulobuterol (theoretical)<\/li><li>Verapamil (probable)<\/li><li>Vilanterol (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><\/ul>"},{"id":"jt69s4b15","title":"Moderate","mono":"<ul><li>Acarbose (probable)<\/li><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Acetyldigoxin (probable)<\/li><li>Albiglutide (probable)<\/li><li>Alfuzosin (probable)<\/li><li>Alogliptin (probable)<\/li><li>Amlodipine (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Arbutamine (probable)<\/li><li>Aspirin (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Bunazosin (probable)<\/li><li>Canagliflozin (probable)<\/li><li>Celecoxib (probable)<\/li><li>Chlorpropamide (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Cimetidine (probable)<\/li><li>Clonixin (probable)<\/li><li>Dapagliflozin (probable)<\/li><li>Deslanoside (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Digitoxin (probable)<\/li><li>Digoxin (probable)<\/li><li>Dipyrone (probable)<\/li><li>Dobutamine (probable)<\/li><li>Doxazosin (probable)<\/li><li>Dulaglutide (probable)<\/li><li>Empagliflozin (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Exenatide (probable)<\/li><li>Felbinac (probable)<\/li><li>Felodipine (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Indomethacin (probable)<\/li><li>Insulin Aspart, Recombinant (probable)<\/li><li>Insulin Degludec (probable)<\/li><li>Insulin Detemir (probable)<\/li><li>Insulin Glargine, Recombinant (probable)<\/li><li>Insulin Glulisine (probable)<\/li><li>Insulin Human Inhaled (probable)<\/li><li>Insulin Human Isophane (NPH) (probable)<\/li><li>Insulin Human Regular (probable)<\/li><li>Insulin Lispro, Recombinant (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Lacidipine (probable)<\/li><li>Lercanidipine (probable)<\/li><li>Linagliptin (probable)<\/li><li>Liraglutide (probable)<\/li><li>Lixisenatide (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Manidipine (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Metformin (probable)<\/li><li>Metildigoxin (probable)<\/li><li>Mibefradil (probable)<\/li><li>Miglitol (probable)<\/li><li>Morniflumate (probable)<\/li><li>Moxisylyte (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nateglinide (probable)<\/li><li>Nepafenac (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nifedipine (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimesulide (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Parecoxib (probable)<\/li><li>Phenoxybenzamine (probable)<\/li><li>Phentolamine (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Pioglitazone (probable)<\/li><li>Piroxicam (probable)<\/li><li>Pramlintide (probable)<\/li><li>Pranidipine (probable)<\/li><li>Prazosin (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Repaglinide (probable)<\/li><li>Rifampin (probable)<\/li><li>Rifapentine (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Rosiglitazone (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Saxagliptin (probable)<\/li><li>Sitagliptin (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>St John's Wort (probable)<\/li><li>Sulindac (probable)<\/li><li>Tamsulosin (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Terazosin (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Trimazosin (probable)<\/li><li>Urapidil (probable)<\/li><li>Valdecoxib (probable)<\/li><li>Vildagliptin (probable)<\/li><\/ul>"}]},"5":{"id":"jt69s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Bradyarrhythmia (3% to 10%), Hypotension (1.8% to 20.2%), Peripheral edema (1% to 7%)<\/li><li><b>Endocrine metabolic:<\/b>Abnormal weight gain (10% to 12%), Hyperglycemia (5% to 12%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (2% to 12%)<\/li><li><b>Neurologic:<\/b>Dizziness (6% to 33%)<\/li><li><b>Reproductive:<\/b>Erectile dysfunction (13.5%)<\/li><li><b>Other:<\/b>Fatigue (24%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Atrioventricular block (greater than 1% to 3%)<\/li><li><b>Dermatologic:<\/b>Erythema multiforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Hematologic:<\/b>Aplastic anemia<\/li><li><b>Ophthalmic:<\/b>Intraoperative floppy iris syndrome<\/li><li><b>Respiratory:<\/b>Asthma with status asthmaticus (rare)<\/li><\/ul>"},"6":{"id":"jt69s6","title":"Drug Name Info","sub":{"0":{"id":"jt69s6b17","title":"US Trade Names","mono":"Coreg<br\/>"},"2":{"id":"jt69s6b19","title":"Class","mono":"<ul><li>Alpha\/Beta-Adrenergic Blocker<\/li><li>Cardiovascular Agent<\/li><\/ul>"},"3":{"id":"jt69s6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jt69s6b21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"jt69s7","title":"Mechanism Of Action","mono":"<ul><li>Systemic: Carvedilol is a nonselective beta-adrenergic blocking agent with alpha 1-adrenergic blocking activity and no intrinsic sympathomimetic activity . The exact mechanism of the antihypertensive effect produced by beta-adrenergic blockade is not known, but may involve suppression of renin production . The beta-adrenergic blocking activity of carvedilol decreases cardiac output, exercise- and\/or isoproterenol-induced tachycardia, and reflex orthostatic tachycardia . The alpha 1-adrenergic blocking activity of carvedilol blunts the pressor effect of phenylephrine, causes vasodilation, and reduces peripheral vascular resistance . The effect of alpha 1-adrenergic blockade is a reduction in standing blood pressure (more than supine), potentiating symptoms of postural hypotension and possibly syncope .<\/li><li>The mechanism by which carvedilol produces a beneficial effect in congestive heart failure is not known, but may be attributable to beta-adrenergic blockade and vasodilation .<\/li><\/ul>"},"8":{"id":"jt69s8","title":"Pharmacokinetics","sub":[{"id":"jt69s8b23","title":"Absorption","mono":"Systemic: Rapid and extensive; Bioavailability: 25 to 35%; food slows absorption <br\/>"},{"id":"jt69s8b24","title":"Distribution","mono":"Systemic: Vd: 115 L <br\/>"},{"id":"jt69s8b25","title":"Metabolism","mono":"Systemic: Hepatic: extensively via P450 2D6 pathway; Active metabolite: 4'-hydroxyphenyl  <br\/>"},{"id":"jt69s8b26","title":"Excretion","mono":"Systemic: Fecal\/biliary<br\/>"},{"id":"jt69s8b27","title":"Elimination Half Life","mono":"Systemic: 7 to 10 h <br\/>"}]},"9":{"id":"jt69s9","title":"Administration","mono":"<b>Oral<\/b><br\/>take with food <br\/>"},"10":{"id":"jt69s10","title":"Monitoring","mono":"<ul><li>angina: reduction in anginal pain<\/li><li>congestive heart failure: decreased signs and symptoms of cardiac failure<\/li><li>hypertension: blood pressure<\/li><li>heart rate, symptoms of arterial insufficiency<\/li><li>renal function; in patients with ischemic heart disease or diffuse vascular disease<\/li><\/ul>"},"11":{"id":"jt69s11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 3.125 MG, 6.25 MG, 12.5 MG, 25 MG<br\/><\/li><li><b>Coreg<\/b><br\/>Oral Tablet: 3.125 MG, 6.25 MG, 12.5 MG, 25 MG<br\/><\/li><\/ul>"},"12":{"id":"jt69s12","title":"Toxicology","sub":[{"id":"jt69s12b31","title":"Clinical Effects","mono":"<b>CARVEDILOL <\/b><br\/>USES: Myocardial infarction, angina pectoris, heart failure, and hypertension. PHARMACOLOGY: Carvedilol is a non-selective beta-adrenergic blocking agent with alpha 1-adrenergic blocking activity and no intrinsic sympathomimetic activity. The beta-adrenergic blocking activity of carvedilol decreases cardiac output, exercise-induced tachycardia, and reflex orthostatic tachycardia. The alpha 1-adrenergic blocking activity of carvedilol causes vasodilation and reduces peripheral vascular resistance. The effect of alpha 1-adrenergic blockade is a reduction in standing blood pressure (more than supine). TOXICOLOGY: Bradycardia and hypotension are the most common effects in beta blocker overdose, and have been reported after carvedilol overdose. The additional component of alpha-1 blocking activity of carvedilol may predispose patients to more pronounced episodes of hypotension. EPIDEMIOLOGY: Poisoning is uncommon but can be severe. MILD TO MODERATE POISONING: Mild hypotension, orthostatic hypotension, dizziness, syncope, and bradycardia. SEVERE POISONING: More severe bradycardia and hypotension, AV dissociation and QRS widening. ADVERSE EFFECTS: Weakness, loss of appetite, profuse sweating, difficult or labored breathing, fever, dizziness, nausea, vomiting, and chest pain. Hepatotoxicity, apparently reversible and rare, has occurred during treatment with carvedilol. <br\/>"},{"id":"jt69s12b32","title":"Treatment","mono":"<b>CARVEDILOL <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: The vast majority of overdoses require only supportive care; activated charcoal is indicated if patients present shortly after ingestion. IV fluids should be administered to support blood pressure. Fall precautions should be ordered to prevent secondary injury due to dizziness or orthostatic hypotension. MANAGEMENT OF SEVERE TOXICITY: Perform early orotracheal intubation for airway protection if the patient has altered mental status. Initially, manage hypotension with IV fluids (500 mL boluses up to 2 liters) and atropine for symptomatic bradycardia. Glucagon should be considered if patient does not respond appropriately to IV fluids. Give catecholamines to those who do not respond to IV fluids and glucagon. No one catecholamine has been shown to be consistently effective; dopamine, norepinephrine, and epinephrine may be considered. High doses may be required. If catecholamines are required despite glucagon and IV fluids, high-dose insulin euglycemia therapy should be considered. Catecholamines should be titrated down when high-dose insulin euglycemia therapy starts to take effect. Intravenous lipid emulsion should be considered in patients with refractory hypotension. Other non-pharmacological therapies include: cardiac pacing, placement of an intra-aortic balloon pump, cardiopulmonary bypass, and extracorporeal membrane oxygenation (ECMO).<\/li><li>Decontamination: PREHOSPITAL: Activated charcoal should be given to those who are able to reliably protect their airway and IV fluids should be given for hypotension or tachycardia. HOSPITAL: Activated charcoal should be given to those who are able to reliably protect their airway. Gastric lavage is generally not indicated; however, in massive overdoses, this might be considered.<\/li><li>Airway management: Perform early in patients with severe intoxication (seizures, dysrhythmias, severe delirium, CNS or respiratory depression).<\/li><li>Hypotensive episode: Initially manage hypotension with intravenous fluids (500 mL boluses up to 2L) and atropine for symptomatic bradycardia.<\/li><li>Antidote: GLUCAGON: Patients who do not respond to intravenous fluids (500 mL boluses up to 2L) and atropine should be treated with glucagon.  Initial dosing is 5 to 15 mg by slow IV push followed by an infusion rate of 5 to 15 mg\/hour. Glucagon may also induce nausea\/vomiting, as well as elevate blood glucose.<\/li><li>Insulin: High-dose insulin euglycemia (HIS) may be considered in patients who do not respond adequately to fluids and catecholamines. HIS is another potential therapy with some positive animal data and case-based human evidence.  Administer a bolus of 1 unit\/kilogram of insulin followed by an infusion of 0.1 to 1 units\/kilogram\/hour, titrated to a systolic blood pressure of greater than 90 to 100 mmHg (bradycardia may or may not respond). Reassess every 30 minutes to titrate insulin infusion. High-dose insulin euglycemia therapy may allow the practitioner to decrease the dose of catecholamines and avoid the adverse effects of prolonged high dose catecholamines. Before, during, and after the therapy, monitor for hypoglycemia and hypokalemia. Administer dextrose bolus to patients with an initial blood glucose of less than 250 mg\/dL (Adult: 25 to 50 mL dextrose 50%; Children: 0.25 g\/kg dextrose 25%). Begin a dextrose infusion of 0.5 g\/kg\/hour in all patients. Monitor blood glucose every 15 to 30 minutes until consistently 100 to 200 mg\/dL for 4 hours, then monitor every hour. Titrate dextrose infusion to maintain blood glucose in the range of 100 to 200 mg\/dL. As the patient improves, insulin resistance abates and dextrose requirements will increase. Supplemental dextrose will be needed for at least several hours after the insulin infusion is discontinued. Administer supplemental potassium initially if patient is hypokalemic (serum potassium less than 2.5 mEq\/L). Monitor serum potassium every 4 hours and supplement as needed to maintain potassium of 2.5 to 2.8 mEq\/L.<\/li><li>Fat Emulsion: Another potential pharmacological treatment is with lipid emulsion therapy, though at this point in time, there is only animal data supporting its use in beta-blocker toxicity; in theory it may be effective for lipid soluble beta blockers such as propranolol.  The dose of 20% lipid emulsion is 1.5 mL\/kg over 1 minute followed immediately with an infusion at a rate of 0.25 mL\/kg\/min, and to repeat the bolus dosing every 3 to 5 minutes up to 3 mL\/kg total dose until circulation is restored.  If BP declines, increase the infusion rate to 0.5 mL\/kg\/min. A maximum dose of 8 mL\/kg is recommended.  For example, the resuscitation of an adult weighing 70 kg is equivalent to taking a 500 mL bag of 20% lipid emulsion and drawing up 50 mL twice and giving it IV push, and then attaching the infusion bag to an IV and running it in over 15 minutes.<\/li><li>Inamrinone: A phosphodiesterase inhibitor which also has theoretical benefit via decreasing breakdown of myocardial cAMP.  The dosing is 1 mg\/kg bolus then 3 to 6 mcg\/kg\/minute.  It is very rarely used because, although it increases inotropy, it may induce peripheral vasodilation and is difficult to titrate due to a relatively long half-life.<\/li><li>Calcium: Calcium chloride has been effective for some beta blocker overdoses that were refractory to conventional therapy. Administer calcium chloride 0.2 mL\/kg or calcium gluconate 0.6 mL\/kg intravenously.<\/li><li>Bradycardia: Atropine, glucagon (50 to 150 mcg\/kg bolus followed by an infusion 1 to 5 mg\/hr), and pacemaker.<\/li><li>Conduction disorder of the heart: QRS widening or ventricular tachycardia may respond to sodium bicarbonate.  A reasonable starting dose is 1 to 2 mEq\/kg bolus, repeat as needed; endpoints include resolution of dysrhythmias, narrowing of QRS complex and blood pH 7.45 to 7.55.  Use lidocaine (1 mg\/kg intravenous bolus followed by 20 to 50 mcg\/kg\/min intravenous infusion) if sodium bicarbonate is not successful.<\/li><li>Seizure: All symptomatic patients should be placed on seizure and fall precautions. Seizures should be treated with benzodiazepines; however, the typical cause of seizures in this population is either due to hypotension or low blood sugar if insulin treatment is ongoing.<\/li><li>Monitoring of patient: Monitor vital signs and mental status. Monitor electrolytes, renal function, troponin, and liver enzymes in patients with significant overdose. Glucose should be monitored hourly in patients receiving high doses insulin\/dextrose therapy. Obtain an ECG and institute continuous cardiac monitoring. Carvedilol blood concentrations are not clinically useful or readily available.<\/li><li>Enhanced elimination procedure: Hemodialysis is not expected to be of benefit for removal of carvedilol after an overdose due to its high degree of plasma protein binding (greater than 98%) and large volume of distribution.<\/li><li>Patient disposition: HOME CRITERIA: Asymptomatic adults with unintentional ingestions of 50 mg or less and asymptomatic children with unintentional ingestions of 0.5 mg\/kg or less can be monitored at home. OBSERVATION CRITERIA: Patients with deliberate ingestions, symptomatic patients, adults ingesting more than 50 mg, and children ingesting more than 0.5 mg\/kg should be referred to a health care facility for observation for 6 to 8 hours. ADMISSION CRITERIA: Patients with significant persistent CNS depression (weakness, ataxia, vertigo, coma), or those with persistent abnormal vital signs, such as bradycardia and hypotension, should be admitted. Patients with dysrhythmias, severe hypotension, or end organ damage should be admitted to an intensive care setting. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients with severe toxicity (dysrhythmias, severe hypotension, coma), or in whom the diagnosis is not clear.<\/li><\/ul>"},{"id":"jt69s12b33","title":"Range of Toxicity","mono":"<b>CARVEDILOL<\/b><br\/>TOXICITY: An adult developed bradycardia, hypotension, and drowsiness following an overdose of 1,050 mg carvedilol in addition to 10 tablets of zopiclone. THERAPEUTIC DOSE: ADULTS: HEART FAILURE: The recommended starting dose is 3.125 mg orally twice daily for 2 weeks. If tolerated, the dose may then be increased at 2-week intervals to 6.25 mg and 12.5 mg twice daily, up to a maximum dose of 25 mg twice daily in patients weighing 85 kg or less, or up to a maximum of 50 mg twice daily in patients who weigh more than 85 kg. CHILDREN: Adjunctive treatment with twice-daily carvedilol at initial doses starting from 0.05 mg\/kg to 0.09 mg\/kg per dose, titrated every 2 weeks to a maximum of 25 mg per dose, led to improvements in ventricular function in children with ventricular dysfunction or heart failure in small, prospective and retrospective studies. <br\/>"}]},"13":{"id":"jt69s13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring coordination until drug effects are realized, as drug may cause dizziness.<\/li><li>This drug may cause diarrhea, nausea, vomiting, arthralgia, back pain, myalgia, headache, vision disorder, erectile dysfunction, reduced libido, or fatigue.<\/li><li>Instruct patient to report signs\/symptoms of adverse cardiovascular effects such as hypotension (especially in elderly patients), arrhythmias, syncope, palpitations, angina, or edema.<\/li><li>Drug may mask symptoms of hypoglycemia. Advise diabetic patients to carefully monitor blood sugar levels.<\/li><li>Patient should take drug with food.<\/li><li>Advise patient against sudden discontinuation of drug.<\/li><\/ul>"}}}